Venetoclax, a specific BCL-2 inhibitor, is a first-in-class BH3-mimetic that is FDA approved in both CLL and acute myeloid leukaemia (AML). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.